Research, Select, & Monitor Sunday, April 05, 2020 5:57:23 PM ET  
Trade Ideas The Market Industries Stocks Portfolio

Ticker Lookup
UBS AG$8.84($.16)(1.78%)

  Quote | Ranking | Chart | Valuations | Sentiment | News | Earnings | Analysts | More...

Your Target?

  UBS AG vs Drug Manufacturers/Other

UBS Group AG engages in providing financial services to private, corporate and institutional clients. It offers retail banking, corporate and institutional banking, wealth management, asset management, and investment banking. The company's Wealth Management division offers investment management, estate planning, and corporate finance advice, as well as specific wealth management products and services. Its Retail & Corporate division offers financial products and services to retail, corporate, and institutional clients. This division also provides professional services, including fund set-up, accounting, and reporting for traditional investment funds and alternative funds. The company's Investment Bank division is engaged in the sales, trading, and market-making activities across a range of securities; and provides advisory services and access in capital markets. UBS Group AG is headquartered in Zurich, Switzerland.

Engaged in the discovery, development, and commercialization of innovative pharmaceuticals for the treatment of many diseases, either directly or indirectly. Directly treating a disease would involve some sort of drug that could attack the infection itself. An indirect treatment may involve a drug that's used to enhance the body's own antibody production so those antibodies can attack the infection themselves. Not only do some of these companies develop drugs for human use, a good number of them also work on animal or plant diseases as well.
 Totals Company Industry
  Sales: $35,151.0 Mil $101,552.4 Mil
  Market Cap: $32,353.8 Mil $358,214.5 Mil
  Analysts Recommendation: Buy Buy

 Averages Company Industry
  Historic Revenue: 2.2% 205.2%
  Estimated Revenue: (16.6%) (.3%)
  Historic Earnings: (19.1%) (8.1%)
  Estimated Earnings: 3.1% 155.2%
  Stock Price (1 Year): (29.4%) (9.1%)
  Cash per Share: 4.0% 5.6%
  Dividend: N/A N/A
  Trailing PE: N/A N/A
  Forward PE: 7.3 17.4
  Price-to-Sales: .9 N/A
  Price-to-Book: .6 3.7
  Dividend Yield: N/A N/A
  Market Cap: $32,353.8 Mil $14,925.6 Mil
  Net Margin: 12.2% (724.7%)
  Gross Margin: 100.0% 83.9%
  Return on Equity: .1 (.3)
  Return on Assets: .0 (.2)
  Balance Sheet
  Current Ratio: .9 9.6
  Quick Ratio: .9 9.3
  Cash Ratio: .2 8.1
  Debt-to-Equity: 16.8 1.6
  Interest Coverage: .0 1.1
  Relative-Strength Index: 40.2 N/A

 Other companies in Drug Manufacturers/Other Price Market Cap
  Novo Nordisk A\/S  (NVO) $59.84 $141,701.1 Mil
  Vertex Pharmaceuticals Inc.  (VRTX) $238.31 $61,281.4 Mil
  Allergan plc  (AGN) $175.71 $57,682.1 Mil
  Alexion Pharmaceuticals, Inc.  (ALXN) $89.77 $19,875.1 Mil
  BioMarin Pharmaceutical, Inc.  (BMRN) $84.21 $15,126.6 Mil

Register |  Password |  Feedback |  Copyright |  Usage Agreement |  Privacy Policy |  Advertising |  About Us |  Contact Us |  FAQ 

Past performance is not indicative of future results, the logo, and News Selects are trademarks of
Copyright © 1998 - 2020 All rights reserved.